Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2017 Nov 20;34(1):99–106. doi: 10.1002/btpr.2577

Biotransformation of β‐hydroxypyruvate and glycolaldehyde to l‐erythrulose by Pichia pastoris strain GS115 overexpressing native transketolase

Yu‐Chia Wei 1, Stephanie Braun‐Galleani 2, Maria José Henríquez 1, Sahan Bandara 1, Darren Nesbeth 1,
PMCID: PMC5836872  PMID: 29086489

Abstract

Transketolase is a proven biocatalytic tool for asymmetric carbon‐carbon bond formation, both as a purified enzyme and within bacterial whole‐cell biocatalysts. The performance of Pichia pastoris as a host for transketolase whole‐cell biocatalysis was investigated using a transketolase‐overexpressing strain to catalyze formation of l‐erythrulose from β‐hydroxypyruvic acid and glycolaldehyde substrates. Pichia pastoris transketolase coding sequence from the locus PAS_chr1‐4_0150 was subcloned downstream of the methanol‐inducible AOX1 promoter in a plasmid for transformation of strain GS115, generating strain TK150. Whole and disrupted TK150 cells from shake flasks achieved 62% and 65% conversion, respectively, under optimal pH and methanol induction conditions. In a 300 μL reaction, TK150 samples from a 1L fed‐batch fermentation achieved a maximum l‐erythrulose space time yield (STY) of 46.58 g L−1 h−1, specific activity of 155 U gCDW1, product yield on substrate (Yp/s) of 0.52 mol mol−1 and product yield on catalyst (Yp/x) of 2.23g gCDW1. We have successfully exploited the rapid growth and high biomass characteristics of Pichia pastoris in whole cell biocatalysis. At high cell density, the engineered TK150 Pichia pastoris strain tolerated high concentrations of substrate and product to achieve high STY of the chiral sugar l‐erythrulose. © 2017 The Authors Biotechnology Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers Biotechnol. Prog., 34:99–106, 2018

Keywords: Pichia pastoris, transketolase, whole cell biocatalyst, l‐erythrulose, product inhibition

Introduction

Small molecule pharmaceuticals, comprising one or more chiral centers, remain a major product type in modern medicine, comprising two of the top five selling drugs globally in 2016, and five of the top 15.1 Optically pure synthesis of small molecule pharmaceuticals by conventional chemi‐synthetic routes tends to require multiple steps, each of which is typically defined by low product yield. As such, complex small molecules with multiple chiral centers tend to have high production costs due to the need for multiple chemi‐synthetic steps.

This challenge has led to the development of alternate “toolbox” platforms2, 3 including biological routes to controlled, stepwise assembly of the chemical species required to synthesize a final, desired molecule. Such biological routes typically involve the application of enzymes in the place of chemical catalysis, for “biocatalysis” to produce the final compound, over one or more steps. One advantage of enzymes is their promiscuity with respect to the molecules they engage with as substrates, which can enable a given enzyme to be used for a broad range of chemistries.4 Enzymes can also provide exquisite regio‐, chemo‐, and stereo‐selectivity for the synthetic steps they catalyze.

In comparison to chemi‐catalytic conditions, which can require extremes of pH and temperature, biocatalysis is typically performed in mild conditions; 25°C‐37°C and pH 7. Mild conditions can be cheaper to maintain than the harsher conditions of chemi‐catalysis. However, harsh conditions are often unavoidable for upstream process steps such as the conditioning of feedstocks to make them physically and biologically compatible with downstream steps. Transitioning from harsh to mild conditions between process steps typically requires further energy or material inputs and brings significant cost implications.5 Purified enzymes are often active in only mild conditions, but variants can be sourced or engineered that are stable to extremes.6 However, even robust enzyme variants have no capacity to regenerate themselves, as they inevitably accumulate damage and denaturation over time. One option to make enzymes both self‐renewing and tolerant to non‐mild conditions is to deploy them while they are still sequestered within a host cell, so‐called whole cell biocatalysis.

Escherichia coli (E. coli) remains a popular option for whole cell biocatalysis, due to its genetic tractability, robustness, and rapid growth. However, E. coli is vulnerable to lysis by bacteriophage, which are naturally ubiquitous in the environment7 and therefore also in agricultural feed streams. E. coli cells also undergo increasingly lethal cell stress from below pH 5.58 and above pH 8.9 A broad variety of alternative host cells have thus been characterized for their performance as whole cell biocatalysts.10 Yeasts are a major alternative, with no pathogens equivalent to bacteriophage and a broader range of pH tolerance, from pH 3 to pH 7.11

In addition to robustifying a biocatalytic step, whole cell biocatalysis can also enable assembly of multiple enzymes within a single component, the cell, to achieve complex, multi‐stage synthesis.12 These pathway engineering approaches mean that biological routes are emerging as credible alternatives to chemi‐synthesis for production of an ever‐increasing number of small molecule product classes, from biofuels to pharmaceuticals. Engineered pathways can be “hosted” by a cell, or steps taken to integrate some or all of the pathway into the native metabolic networks of the host cell. In the former approach typically lower value, achiral compounds are fed to the host cell and converted to higher value chemicals with defined chiral centers.13 In the latter approach, often termed metabolic engineering, the cells need only be cultivated using a cheap carbon source, often crude waste streams from agriculture, and they will in effect convert this material to a product of higher value, such as a biofuel.14

A particular class of enzymes known as transketolases (EC 2.2.1.1) have been investigated as biocatalytic tools due to their ability to form the asymmetric carbon‐carbon bonds commonly required for chemical synthesis of a broad range of pharmaceuticals, agrochemicals, materials, and food ingredients.15 In nature transketolases require thiamine diphosphate as a cofactor and provide a regulatory function in cellular metabolism, linking the pentose phosphate pathway to glycolysis by catalyzing transfer of a two‐carbon fragment from xylulose to ribose sugars, forming heptulose sugars. Biotechnologists have shown that this activity can be exploited to drive an irreversible reaction when providing β‐hydroxypyruvate (HPA) as the donor of the two‐carbon fragment, resulting in carbon dioxide as one of the reaction products. Transketolases have typically been sourced from genomic data mining of yeasts16 and bacteria17 and used for production of a number of different products including food flavorings, and synthetic precursors of chiral amino alcohols which are valuable intermediates in synthesis of small molecular therapeutics.18

The stereospecificity and enantioselectivity typical of transketolases often results in bio‐catalyzed reaction routes that are more atom‐efficient than their chemo‐catalytic counterparts for a given synthesis step.19 Key measures used to assess the efficacy of a given transketolase system for biocatalysis are activity, substrate‐specificity, and inhibition by products or substrates. If necessary to achieve sufficient conversion, the cost of enzyme purification can also be a key performance measure. E. coli transketolase has been reported to be effective in production of l‐erythrulose when in solution,20 immobilized within a microreactor17 and within living E. coli cells.21

The methylotrophic budding yeast, Pichia pastoris (P. pastoris), is an established laboratory‐scale recombinant protein production platform22 and is gaining traction as an industrial‐scale platform for production of enzymes23 and therapeutics.24 Characteristically low specific yield does not prevent high volumetric yields of recombinant protein25 as P. pastoris can grow rapidly to high biomass concentration, with 40% v/v WCW typically achieved. Methylotrophic yeasts have also been observed to tolerate extreme overexpression of the alcohol oxygenase 1 (Aox1p) enzyme essential for methanol utilization, to a level where 30% of cell biomass can be taken up with this enzyme during growth phase.26

The effectiveness of P. pastoris as a whole cell biocatalyst has been investigated for ester biosynthesis,27 acetophenone reduction.28 d‐Amino acid oxidation29 and kinetic resolution of racemic α‐methylbenzylamine to 99% ee (R)‐α‐methylbenzylamine.13 A cell‐surface display strategy has also been used for expression of active lipase by a P. pastoris whole cell biocatalyst.30

Previous work showed that overexpression of a native transketolase within an E. coli whole cell biocatalyst could achieve asymmetrization of the prochiral compounds β‐hydroxypyruvate (HPA) and glycolaldehyde (GA) to generate up to 20 mM l‐erythrulose (ERY), for subsequent steps in a de novo biocatalytic pathway, over a 17.5 h reaction period.21 In this study, we sought to establish if the same asymmetrization could be achieved using P. pastoris cells overexpressing a native transketolase. We also wished to test if the higher biomass achievable in P. pastoris could be harnessed to achieve higher levels of ERY production compared to the E. coli whole cell biocatalyst.

Materials and Methods

Construction of the TK150 native transketolase overexpressor strain

All DNA manipulations, unless otherwise stated, were performed using standard molecular biology techniques. The genome of P. pastoris strain GS115 (Invitrogen, Carlsbad, CA), recently assigned31 as Komagataella phaffii (ATCC 20864), encodes a transketolase (TK) open reading frame (ORF) at locus PAS_chr1–4_0150 (Genbank: CAY67980.1). A single colony of P. pastoris strain GS115 was boiled in water to provide genomic DNA template for preparative polymerase chain reaction (PCR). Primers CACAATGTCTGATCTCTTAGC (start codon underlined) and AAACTACGCATGAACAGACTC (stop codon underlined) were provided by Eurofins MWG Operon (Ebersberg, Germany) and used to PCR‐amplify a 2.04 kb fragment from the PAS_chr1–4_0150 locus32 encoding the TK ORF. The resultant PCR fragment was subcloned into the pCR‐BluntII‐TOPO vector (Invitrogen) between a pair of Eco RI restriction sites and its identity confirmed by sequencing. The TK ORF fragment was then subcloned from pCR‐BluntII‐TOPO into the P. pastoris expression vector, pAO815 (Invitrogen), by non‐directional ligation into a lone Eco RI site and a Hind III digest used to confirm orientation. The resultant plasmid, designated pAOX0150‐TK, was linearized with the restriction enzyme Stu I and used to transform P. pastoris GS115 following manufacturer's instruction.33 Successful transformation generated a new strain, designated TK150, in which the methanol utilization phenotype was preserved as Mut+ and the histidine biosynthesis phenotype was converted from His4 to HIS4.

Shake flask cultivation

Cells were typically cultivated in 50 mL buffered glycerol complex medium (BMGY) broth (1% w/v yeast extract, 2% w/v peptone, 100 mM potassium phosphate pH 6, 1.34% w/v yeast nitrogen without amino acids, 1% v/v glycerol, and 0.4 µg/mL biotin) in a 250 mL shake flask incubated at 30°C, with 250 rpm agitation for 15 h, after which an OD600 = 2 was reached. Glycerol stocks for cell cryopreservation were made by pelleting cells at OD600 = 2 by centrifugation at 13,000 rpm (Eppendorf 5415R centrifuge, Eppendorf UK, Ltd, Cambridge, UK) for 5 min at room temperature and resuspending cells in a solution of 5 volumes of BMGY plus 3 volumes of 80% glycerol, then transferring 1.5 mL aliquots into 2 mL cryo‐vials. Working cell banks (WCB) of 20–30 vials were generated for each strain. Typically, 100 mL of BMGY medium in a 250 mL conical flask were inoculated with 1 mL of a glycerol stock. For investigation of recombinant TK activity, cells were grown to OD600 = 2 then pelleted as before. To induce expression of TK under control of the AOX1 promoter, cells were resuspended again to OD600 = 2 in buffered methanol (BMMY) complex medium (recipe as BMGY but 1% v/v glycerol substituted for 0.5% v/v methanol) and incubated as above with pure methanol added to 0.5% v/v every 24 h post‐induction initiation.

Bioreactor cultivation

A 100 mL culture of TK150 cells in BMGY media in 500 mL shake flasks was incubated at 30°C with agitation at 250 rpm until OD600 = 80 was achieved. 40 mL of this culture were used to inoculate 600 mL of fermentation basal salts medium (BSM) containing 4% w/v glycerol, to give an initial OD600 of 5 in a 1L Infors bioreactor (Multifors 1, INFORS HT, Switzerland). BSM consisted of 26.7 mL 85% w/v H2PO4, 0.93 g CaSO4, 18.2 g K2SO4, 14.9 g MgSO4.7H2O, 4.13 g KOH, 40 g glycerol, and 12 mL “Pichia Trace Metal 1” (PTM1) solution (6.0 g/L CuSO45H2O, 0.08 g/L Nal, 3.0 g/L MnSO4.H2O, 0.2 g/L Na2MoO4.2H2O, 0.02 g/L H3BO3, 0.5 g/L CoCl2, 20.0 g/L ZnCl2, 65.0 g/L FeSO4.7H2O, 0.2 g/L biotin, and 5.0 mL/L 96% H2SO4) per liter dH2O. During this initial trophophase of glycerol batch growth, a dissolved oxygen set point of 20% was used for control of pure oxygen feeding. Bioreactor cultivation was performed as per Invitrogen protocol.29 Three rates of methanol feed were introduced for induction, 3.6 mL/h/L initially (M1), then 7.3 mL/h/L (M2), and a final feed rate of 10.9 mL/h/L (M3).

Preparation of solutions of whole and disrupted cells for biocatalysis

Bioreactor and shake flask samples were centrifuged at 13,000 rpm for 20 min at 4°C to pellet cells. Whole cells were re‐suspended in pH 7 Tris buffer and placed on ice to inhibit further growth. A Soniprep 150 sonicator (MSE, London, UK) was used to subject samples to a 10 s cycle of 100% amplitude sonication, followed by 10 s rest, three times.

Reaction conditions

A 100 μL solution containing whole cells or disrupted cells was initially incubated with 15 μL of a 2.4 mM solution of the cofactor thiamine pyrophosphate and 15 μL of 9 mM MgCl2 at room temperature with constant shaking at 150 rpm for 20 min. 50 μL of hydroxypyruvate and 50 μL of glycolaldehyde, both at 300 mM, were then added in addition to 70 μL of 50 mM Tris buffer to a final reaction volume of 300 μL and substrate concentration of 50 mM. Higher substrates concentrations, of up to 2 M, were achieved by using the required volumes of 7 M stock solutions of each substrate, again in a total final reaction volume of 300 μL.

l‐Erythrulose measurement

The Dionex HPLC system (Camberley, UK) and its monitored software Chromeleon client 6.60 were used for reaction analysis. The system contains an AD20 UV/vis absorbance detector, a FAMOS autosampler, an oven and a GP50 gradient pump. A 15 min isocratic assay, as reported by Mitra and Woodley,34 was used to analyze HPA and ERY, using a 300 mm × 7.8 mm HPX‐87H Reverse Phase Column (Bio‐Rad Amines, CA, USA). Mobile phase was prepared with 0.1% trifluoroacetic acid (TFA) and dH2O at a constant temperature of 60°C, flow rate 0.6 mL/min. Prior to analysis samples were quenched and diluted into 10% in 0.1%v/v TFA.

Results and Discussion

Growth and methanol tolerance of TK150 strain in shake flasks

A novel P. pastoris GS115 strain, designated “TK150,” was generated in which a native transketolase, encoded at the locus CAY67980.1 (Genbank), was placed under the control of the AOX1 promoter. Performance in shake flasks achieved by the TK150 strain was comparable to that of the parental strain in the presence of methanol (0.5% v/v) but the TK150 strain achieved higher optical density (OD) from day three post‐induction onward (Figure 1). Nocon et al.35 showed that transketolase overexpression increased metabolic flux in P. pastoris X‐33 strain so we hypothesized transketolase overexpression may also increase the capacity of P. pastoris to metabolize methanol. To test this hypothesis, we cultivated TK150 and GS115 strains in 200 mL shake flasks in 50 mL complex media (see Methods) supplemented with methanol in concentrations of 0%, 0.25‐1%, and 5% v/v. Figure 2 shows that both TK150 and parental GS115 strains grew to a similar level in the presence of 0.25‐1% v/v methanol. The highest concentration of 5% v/v methanol suppressed completely growth of the parental GS115 strain but still enabled growth of TK150, decreasing growth rate by half when compared to the supplementation of 0.25‐1% v/v. Interestingly, the TK150 strain also reached higher cell density than GS115 in the methanol‐free condition.

Figure 1.

Figure 1

Shake flask growth performance of P. pastoris TK150 transketolase overexpressor strain. P. pastoris strains GS115 or TK150 (TK) were cultivated in 250 mL shake flasks in 50 mL BMGY media. Samples were removed at the indicated time points and OD600 measured. Error bars indicate standard deviation among three biological repeats of the experiment.

Figure 2.

Figure 2

Methanol tolerance of the P. pastoris TK150 transketolase overexpressor strain. P. pastoris strains GS115 or TK150 (TK) were cultivated in 250 mL shake flasks in 50 mL BMMY media supplemented with methanol (MeOH) to the percentage v/v indicated. Samples were removed at the indicated time points and OD600 measured. Error bars indicate standard deviation among three biological repeats of the experiment.

Transketolase activity in whole and disrupted TK150 cells

We next established the profile of methanol‐induced transketolase activity appearance in whole cells and cells disrupted by sonication (Figure 3). Activity was measured by percentage conversion of 50 mM HPA and GA substrates to ERY. TK150 strain cells were grown in the absence of methanol to OD600 = 2 and from then onwards cultivated in the presence of daily batches of methanol to 0.5% v/v. Figure 3 shows that, for the TK150 strain, transketolase activity peaked at 48 h post‐induction, as measured in both whole cells and sonicates. For TK150 whole cells, conversion remained within a 45–60% range for from 1 to 5 days post‐induction. This robustness in performance for whole cells may be due to cellular homeostatic processes, such as chaperone activity, working to maintain the folding and stability of cellular proteins during shake cultivation and incubation with fed substrates. However, for disrupted TK150 cells conversion dropped dramatically at day three, down to less than 10%. This steep drop might be due to the fact little or no homeostatic activity is present in disrupted cells to maintain protein stability during incubation with fed substrates. No significant activity was observed for the parental GS115 strain in the same experiments.

Figure 3.

Figure 3

Transketolase activity of TK50 strain cultivated in shake flasks. P. pastoris strains GS115 or TK150 (TK) were cultivated in 0.5% v/v methanol BMMY media. At the indicated time points samples were removed and prepared for incubation with 50 mM β‐hydroxypyruvate and 50 mM glycolaldehyde either as whole (WC) or disrupted cells (Dis), as described in Methods. The concentration of l‐erythrulose produced was measured by HPLC and plotted as a percentage of the starting concentration of substrates (50 mM), as a level of conversion. Error bars indicate standard deviation among three biological repeats of the experiment.

Transketolase activity across pH 5–9

Conditioning steps, such as adding solvents or altering pH, are sometimes necessary to render a given feed stream compatible with the addition of enzymes or whole cell biocatalysts in subsequent steps of a bioprocess. As such, robustness to a range of pH values can be an industrially advantageous property for biocatalysts. To investigate pH tolerance, we used whole cells and sonicates from 48‐h induction in shake flasks to determine optimal pH conditions for bioconversion (Figure 4). We measured percentage conversion of 50 mM HPA and GA to ERY in the presence of buffers at a range of different pH values as indicated in Figure 4. Across pH 5–7, cell sonicates maintained their level of activity in a phosphate buffer (Figure 4A). Using a Tris buffer increased sonicate transketolase activity at pH 7 compared to phosphate buffer. This high activity in Tris‐based buffer was maintained at pH 8 but decreased at pH 9.

Figure 4.

Figure 4

Influence of pH and buffer choice on transketolase activity. P. pastoris strains GS115 or TK150 (TK) were cultivated in 0.5% v/v methanol BMMY media as in Figure 3. Samples were removed and prepared for incubation with 50 mM β‐hydroxypyruvate and 50 mM glycolaldehyde either as whole (WC) or disrupted cells (Dis). During this preparation samples were resuspended in either Tris (Tris) or Phosphate (Phos) buffer at the indicated final pH. Conversion of substrates to l‐erythrulose was measured and plotted as in Figure 3. Data set depicted is representative of three biological repeats of the experiment.

Counter to our expectations, transketolase activity in TK150 whole cells was much lower in phosphate buffer across pH 5–7 (Figure 4B) compared to sonicates (Figure 4A). Furthermore, whole cell transketolase activity in phosphate buffer at pH 5 was completely abolished (0% conversion) compared to the same condition for sonicates (70% conversion). This observation was unexpected as Chiruvolu et al.36 report significant P. pastoris cell growth at pH 5. Sauer et al.37 measured an intracellular pH of 7.1 within P. pastoris cells immersed in pH 5 growth media. Achieving this intracellular pH control requires the employment of cellular energy and mechanisms to drive reverse chemi‐osmosis across cell membranes. Such homeostatic processes may compromise expression of the transketolase transgene, the stability of the enzyme or the permeability of cell membranes to the fed transketolase substrates, via as yet uncharacterized mechanisms. Further research in future will be required to establish if such affects cause the abolished activity at pH 5. The parental GS115 strain resulted in no significant transketolase activity across the different pH conditions (Figure 4).

Cultivation of TK150 strain to high cell density in a bioreactor

A major advantage of P. pastoris for industrial application is its ability to achieve higher levels of biomass, of up to 60% WCW/v, than the typical values obtained for E. coli or Saccharomyces cerevisiae (S. cerevisiae). This can result in high levels of a recombinant enzyme or protein per unit volume even if per cell yield is low.38 Consequently, we cultivated P. pastoris strain TK150 to high cell density and measured the level of bioconversion achieved. Figure 5 details the typical growth profile observed during cultivation of P. pastoris cells in a 1 L Infors bioreactor, reaching wet cell weight (WCW) of 600 g/L using the cultivation regime reported by Templar et al.39 Samples were taken immediately prior to the start of methanol feeding (indicated as M1 in Figure 5) and then 33 h and 58 h after the start of methanol feeding.

Figure 5.

Figure 5

Bioreactor cultivation of TK150 strain to high cell density. Strain TK150 was grown in a bioreactor to high cell density using a protocol in which methanol feeding commenced at the point post‐inoculation indicated by the M1 bar. Methanol feed rate is stepped up at M2 and subsequently at M3. Wet cell weight (WCW) and dry cell weight (DCW) for each sample are indicated (see inset key). Samples taken at zero, 33 and 58 h after the start of induction (M1) were used to test biocatalytic performance. Data set depicted is representative of three biological repeats of the experiment.

Bioconversion by the TK150 strain at high cell density

To establish if the high biomass achievable by P. pastoris can translate into enhanced biocatalytic performance, samples taken from the Infors 1 L bioreactor at zero, 33 and 58 h post‐induction were assessed for their volumetric activity in bioconversion of HPA and GA to ERY (Figure 6). For whole cells, the greatest conversion percentage, nearing 65%, was achieved with the 33‐h sample and with 0.5 M substrates (Figure 6A). The highest amount of ERY produced was 776.4 mM, again with the 33‐h post induction sample but with a concentration of 1.5 M substrate provided (Figure 6B). For sonicates, conversion fell relative to whole cells, with the highest bioconversion level, of 38%, achieved with the 58‐h post‐induction sample and 0.5 M substrates (Figure 6C). The highest concentration of ERY produced by sonicates was 110 mM, again with the 58‐h post‐induction sample but with 1.0 M substrates (Figure 6D). A response surface (Figure 7) was generated to map regions of high whole cell bioconversion to ERY as a function of induction period and substrate concentration. For cells harvested at 33 h post methanol induction, maximum conversion was achieved upon feeding with 0.5 M substrates. For cells harvested at 58 h post methanol induction, maximum conversion was achieved upon feeding with 1 M substrates. These distinct maxima were not expected. In general, the percentage of viable cells decreases over the idiophase of high cell density bioreactor cultivation. We suggest this viability difference between the 33 h and 55 h post induction samples is likely to be a key determinant of the different performance profiles. Future research will be needed to clarify this.

Figure 6.

Figure 6

Effect of substrate concentration, cell density and induction period on TK150 strain whole cell biotransformation. Bioreactor samples, taken at zero, 33 and 58 h post induction, were used to test biocatalytic performance for solutions of whole cells (A and B) and cell sonicates (C and D). Percentage conversion of substrates to l‐erythrulose (A and C) was plotted alongside accumulation of l‐erythrulose in molar and mass concentration terms (B and D). Error bars indicate standard deviation among three biological repeats of the experiment. Key in plot B applies to all plots.

Figure 7.

Figure 7

Response surface for TK150 strain whole cell biotransformation. Figure 6E data gathered for percentage conversion of substrates to l‐erythrulose (ERY) were plotted as a function of both the time post‐induction and the initial substrate concentration present in the reaction mixture. Average values were used to generate the response surface. Standard deviation among three biological repeats of the experiment is omitted for graphical brevity.

TK150 strain whole cell biocatalyst performance

Research into the usefulness of P. pastoris as whole cell biocatalysts continues to accumulate, including the use of killed40 or permeabilized41, 42 whole cells. Schrewe et al.10 discuss a selection of performance metrics, distinct from those commonly applied for cell‐free enzymes, to meaningfully characterize and compare whole cell biocatalysts. Table 1 shows a selection of Schrewe metrics for the biocatalytic performance of the whole cells in this study, for the sample taken 33 h post‐induction. Ingram et al.21 constructed an E. coli whole cell biocatalyst overexpressing native transketolase for conversion of β‐hydroxypyruvic acid and glycolaldehyde to l‐erythrulose. They reported a maximum l‐erythrulose production of 20 mM after a 17.5 h reaction duration. This equates to a STY of 13.7 mg L−1 h−1 which is 3,400‐fold lower than the activity of 46.58 g L−1 h−1 we report here for P. pastoris whole cell biocatalysis.

Table 1.

Schrewe Metrics Whole Cell Biocatalysis. Date Gathered Using the 33‐h Post Induction Sample of P. pastoris Strain TK150 Cultivated in a 1 L Bioreactor

Reaction Values
Starting [GA], [HPA] 1.5 M
[ERY] after 2 h reaction 0.7764 M
µM ERY per min 6469.8
[ERY] after 2 h reaction 93.2 g/L
g/L DCW in sample 125.25
g/L DCW in reaction 41.75
Schrewe metrics
STY (g product L−1 h−1) 46.58 g L−1 h−1
Specific activity (U gCDW1) (U = μmole min−1) 155 U gCDW1
Y p/s (molproduct molsubstrate1) 0.52 mol mol−1
Y p/x (g product gCDW1) 2.23 g gCDW1

Conclusions

The property of P. pastoris that already significantly benefits its use in recombinant protein production, namely rapid growth to high biomass, was also used here to intensify biocatalysis. A robust and novel recombinant P. pastoris whole cell biocatalyst, TK150, overexpressing a native transketolase gene was developed as a hosted, one‐step biocatalytic pathway to bring about asymmetric carbon‐carbon bind formation in the production of l‐erythrulose from achiral substrates. The P. pastoris whole cell biocatalyst remained active from pH 7–9, and achieved performance metrics in line with other P. pastoris‐based biocatalysts and orders of magnitude greater than a bacterial equivalent.

Acknowledgments

We gratefully acknowledge the Government of Taiwan, People's Republic of China, who supported the doctoral studies of Y‐C.W., the Government of Chile and its Program CONICYT‐Becas Chile (72120390), who supported the doctoral studies of MJ.H., and the ERA‐IB IPCRES Consortium, funded in the UK by the BBSRC (BB/M004880/1), who supported all other authors.

Literature Cited

  • 1. Philippidis, A. The Top 15 Best‐Selling Drugs of 2016. Prospect of Price Curbs May Dent Future Results for Blockbusters. Genetic Engineering News 2017. https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868
  • 2. Breuer M, Ditrich K, Habicher T, Hauer B, Kesseler M, Sturmer R, Zelinski T. Industrial methods for the production of optically active intermediates. Angew Chem Int Ed Engl. 2004;43:788–824. [DOI] [PubMed] [Google Scholar]
  • 3. Verho O, Bäckvall JE. Chemoenzymatic dynamic kinetic resolution: a powerful tool for the preparation of enantiomerically pure alcohols and amines. J Am Chem Soc. 2015;137:3996–4009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Littlechild JA. Improving the ‘tool box’ for robust industrial enzymes. J Ind Microbiol Biotechnol. 2017;44:711–720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Parisutham V, Kim TH, Lee SK. Feasibilities of consolidated bioprocessing microbes: from pretreatment to biofuel production. Bioresour Technol. 2014;161:431–440. [DOI] [PubMed] [Google Scholar]
  • 6. Yu H, Yan Y, Zhang C, Dalby PA. Two strategies to engineer flexible loops for improved enzyme thermostability. Sci Rep. 2017;7:41212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Sturino JM, Klaenhammer TR. Engineered bacteriophage‐defence systems in bioprocessing. Nat Rev Microbiol. 2006;4:395–404. [DOI] [PubMed] [Google Scholar]
  • 8. Seputiene V, Daugelavicius A, Suziedelis K, Suziedeliene E. Acid response of exponentially growing Escherichia coli K‐12. Microbiol Res. 2006;161:65–74. [DOI] [PubMed] [Google Scholar]
  • 9. Padan E, Bibi E, Ito M, Krulwich TA. Alkaline pH homeostasis in bacteria: new insights. Biochim Biophys Acta 2005;1717:67–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Schrewe M, Julsing MK, Bühler B, Schmid A. Whole‐cell biocatalysis for selective and productive C‐O functional group introduction and modification. Chem Soc Rev. 2013;42:6346–6377. [DOI] [PubMed] [Google Scholar]
  • 11. Yu Y, Zhou X, Wu S, Wei T, Yu L. High‐yield production of the human lysozyme by Pichia pastoris SMD1168 using response surface methodology and high‐cell‐density fermentation. Electron J. Biotechnol. 2014;17:311–316. [Google Scholar]
  • 12. Galanie S, Thodey K, Trenchard IJ, Filsinger Interrante M, Smolke CD. Complete biosynthesis of opioids in yeast. Science 2015;349:1095–1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Bea H‐S, Seo Y‐M, Cha M‐H, Kim B‐G, Yun H. Kinetic resolution of α‐methylbenzylamine by recombinant Pichia pastoris expressing ω‐transaminase. Biotechnol Bioprocess Eng. 2010;15:429–434. [Google Scholar]
  • 14. Alper H, Moxley J, Nevoigt E, Fink GR, Stephanopoulos G. Engineering yeast transcription machinery for improved ethanol tolerance and production. Science 2006;314:1565–1568. [DOI] [PubMed] [Google Scholar]
  • 15. Payongsri P, Steadman D, Hailes HC, Dalby PA. Second generation engineering of transketolase for polar aromatic aldehyde substrates. Enzyme Microb Technol. 2015;71:45–52. [DOI] [PubMed] [Google Scholar]
  • 16. Ranoux A, Karmee SK, Jin J, Bhaduri A, Caiazzo A, Arends IW, Hanefeld U. Enhancement of the Substrate Scope of Transketolase. ChemBioChem 2012;13:1921–1931. [DOI] [PubMed] [Google Scholar]
  • 17. Halima AA, Szita N, Baganz F. Characterization and multi‐step transketolase‐ω‐transaminase bioconversions in an immobilized enzyme microreactor (IEMR) with packed tube. J Biotechnol. 2013;168:567–575. [DOI] [PubMed] [Google Scholar]
  • 18. Zheng G‐W, Xu J‐H. New opportunities for biocatalysis: driving the synthesis of chiral chemicals. Curr Opin Biotechnol. 2011;22:784–792. [DOI] [PubMed] [Google Scholar]
  • 19. Martinez‐Montero A, Fernandez S, Yogesh S, Sanghvi SY, Gotor V, Ferrero M. An expedient biocatalytic procedure for a basic site precursors useful in oligonucleotide synthesis. Org Biomol Chem. 2011;9:5960–5966. [DOI] [PubMed] [Google Scholar]
  • 20. Payongsri P, Steadman D, Strafford J, MacMurray A, Hailes HC, Dalby PA. Rational substrate and enzyme engineering of transketolase for aromatics. Org Biomol Chem. 2012;10:9021–9029. [DOI] [PubMed] [Google Scholar]
  • 21. Ingram CU, Bommer M, Smith ME, Dalby PA, Ward JM, Hailes HC, Lye GJ. One‐pot synthesis of amino‐alcohols using a de‐novo transketolase and beta‐alanine: pyruvate transaminase pathway in Escherichia coli . Biotechnol Bioeng. 2007;96:559–569. [DOI] [PubMed] [Google Scholar]
  • 22. Tolner B, Smith L, Begent RH, Chester KA. Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc. 2006;1:1006–1021. [DOI] [PubMed] [Google Scholar]
  • 23. Rabert C, Weinacker D, Pessoa A Jr, Farías JG. Recombinant proteins for industrial uses: utilization of Pichia pastoris expression system. Braz J Microbiol. 2013;44:351–356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Su M, Chang W, Zhang K, Cui M, Wu S, Xu T. Expression and purification of recombinant ATF‐mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris . Oncol Rep. 2016;35:1179–1185. [DOI] [PubMed] [Google Scholar]
  • 25. Kunert R, Gach J, Kainger H. Expression of a Fab fragment in CHO and Pichia pastoris—a comparative case study . BioProcess Int. 2008;5:34–40. [Google Scholar]
  • 26. Gellisen G. Heterologous protein production in methylotrophic yeasts. Appl. Microbiol. Biotechnol. 2000;54:741–750. [DOI] [PubMed] [Google Scholar]
  • 27. Zhuang S, Fu J, Powell C, Huang J, Xia Y, Yan R. Production of medium‐chain volatile flavour esters in Pichia pastoris whole‐cell biocatalysts with extracellular expression of Saccharomyces cerevisiae acyl‐CoA:ethanol O‐acyltransferase Eht1 or Eeb1. Springerplus 2015;4:467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Homola P, Kurák T, Illeová V, Polakovič M. Cultivation of Pichia capsulata as a whole‐cell biocatalyst with NADH‐dependent alcohol dehydrogenase activity for R‐1‐phenylethanol production. Food Bioprod Process. 2015;96:126–132. [Google Scholar]
  • 29. Abad S, Nahalka J, Bergler G, Arnold SA, Speight R, Fotheringham I, Nidetzky B, Glieder A. Stepwise engineering of a Pichia pastoris d‐amino acid oxidase whole cell catalyst. Microb Cell Fact. 2010;9:24–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Jiang Z, Gao G, Ren R, Tao X, Ma Y, Wei D. Efficient display of active lipase LipB52 with a Pichia pastoris cell surface display system and comparison with the LipB52 displayed on Saccharomyces cerevisiae cell surface. BMC Biotechnol. 2008;8:4–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Kurtzman CP. Description of Komagataella phaffii sp. nov. and the transfer of Pichia pseudopastoris to the methylotrophic yeast genus Komagataella . Int J Syst Evol Microbiol. 2005;55:973–976. [DOI] [PubMed] [Google Scholar]
  • 32. De Schutter K, Lin YC, Tiels P, Van Hecke A, Glinka S, Weber‐Lehmann J, Rouzé P, Van de Peer Y, Callewaert N. Genome sequence of the recombinant protein production host Pichia pastoris . Nat Biotechnol. 2009;27:561–566. [DOI] [PubMed] [Google Scholar]
  • 33.Invitrogen: Pichia Fermentation Process Guidelines (Version B 053002). Invitrogen 2002. https://tools.thermofisher.com/content/sfs/manuals/pichiaferm_prot.pdf
  • 34. Mitra RK, Woodley JM. A useful assay for transketolase in asymmetric syntheses. Biotechnol Tech. 1996;10:167–172. [Google Scholar]
  • 35. Nocon J, Steiger MG, Pfeffer M, Sohn SB, Kim TY, Maurer M, Rußmayer H, Pflügl S, Ask M, Haberhauer‐Troyer C, Ortmayr K, Hann S, Koellensperger G, Gasser B, Lee SY, Mattanovich D. Model based engineering of Pichia pastoris central metabolism enhances recombinant protein production. Metab Eng. 2014;24:129–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Chiruvolu V, Eskridge K, Cregg J, Meagher M. Effects of glycerol concentration and pH on growth of recombinant Pichia pastoris yeast. Appl Biochem. Biotechnol. 1998;75:163–173. [Google Scholar]
  • 37. Sauer M, Branduardi P, Gasser B, Valli M, Maurer M, Porro D, Mattanovich D. Differential gene expression in recombinant Pichia pastoris analysed by heterologous DNA microarray hybridisation. Microb Cell Fact. 2004;3:17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Krainer FW, Dietzsch C, Hajek T, Herwig C, Spadiut O, Glieder A. Recombinant protein expression in Pichia pastoris strains with an engineered methanol utilization pathway. Microb Cell Fact. 2012;11:22–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Templar A, Woodhouse S, Keshavarz‐Moore E, Nesbeth DN. Influence of Pichia pastoris cellular material on polymerase chain reaction performance as a synthetic biology standard for genome monitoring. J Microbiol Methods 2016;127:111–122. [DOI] [PubMed] [Google Scholar]
  • 40. Martínez D, Menéndez C, Echemendia FM, Pérez ER, Trujillo LE, Sobrino A, Ramírez R, Quintero Y, Hernández L. Complete sucrose hydrolysis by heat‐killed recombinant Pichia pastoris cells entrapped in calcium alginate. Microb Cell Fact. 2014;13:87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Bharathiraja B, Ranjith Kumar R, PraveenKumar R, Chakravarthy M, Yogendran D, Jayamuthunagai J. Biodiesel production from different algal oil using immobilized pure lipase and tailor made rPichia pastoris with Cal A and Cal B genes. Bioresour Technol. 2016;213:69–78. [DOI] [PubMed] [Google Scholar]
  • 42. Schrewe M, Julsing MK, Bühler B, Schmid A. Whole‐cell biocatalysis for selective and productive C‐O functional group introduction and modification. Chem Soc Rev. 2013;42:6346–6377. [DOI] [PubMed] [Google Scholar]

Articles from Biotechnology Progress are provided here courtesy of Wiley

RESOURCES